Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
21-Apr-2025 | 731.9 | 736.95 | 720.8 | 724.6 | 13,914 | 22,53,74,135.55 | 1,70,347 |
22-Apr-2025 | 727.8 | 741.25 | 720.4 | 735.7 | 19,294 | 29,27,67,000.75 | 1,90,720 |
23-Apr-2025 | 744 | 754.85 | 733.3 | 749.15 | 24,803 | 47,34,17,175.9 | 2,67,754 |
24-Apr-2025 | 691 | 695 | 650 | 653.4 | 2,48,766 | 13,52,93,88,448.75 | 76,47,746 |
25-Apr-2025 | 655 | 657 | 628 | 630.1 | 1,42,801 | 2,81,53,73,167.65 | 16,74,821 |
28-Apr-2025 | 630.1 | 631.6 | 614 | 616.95 | 1,42,362 | 3,77,41,39,595.9 | 42,24,744 |
29-Apr-2025 | 618 | 631.7 | 612.25 | 628.9 | 56,868 | 2,15,07,39,581 | 19,57,346 |
30-Apr-2025 | 630 | 640.5 | 626 | 634.05 | 43,371 | 1,32,69,59,653.5 | 12,60,021 |
02-May-2025 | 634 | 636 | 622.3 | 627.95 | 24,536 | 66,32,19,532.75 | 5,97,619 |
05-May-2025 | 630 | 633.4 | 625.4 | 629.2 | 22,175 | 56,62,69,690.2 | 5,30,935 |
06-May-2025 | 631.9 | 634.8 | 616 | 618.75 | 29,902 | 1,26,17,59,873.3 | 13,03,003 |
07-May-2025 | 610.3 | 623.75 | 610.3 | 621.2 | 20,533 | 41,09,83,262.4 | 3,48,888 |
08-May-2025 | 621.2 | 624.3 | 606.2 | 610.7 | 18,765 | 57,37,82,442.9 | 6,07,830 |
09-May-2025 | 601.3 | 615 | 599.55 | 614.1 | 44,043 | 73,75,57,698.85 | 7,10,426 |
12-May-2025 | 616.1 | 627.45 | 612.4 | 625.6 | 28,146 | 73,25,64,971.85 | 6,19,215 |
13-May-2025 | 628 | 638.4 | 625.95 | 629.45 | 30,283 | 69,84,84,657.2 | 6,06,631 |
14-May-2025 | 629.45 | 642 | 627.35 | 640.85 | 30,973 | 63,02,06,196.1 | 5,04,763 |
15-May-2025 | 641 | 642.45 | 635.3 | 638.35 | 13,441 | 26,24,18,801.8 | 1,72,957 |
16-May-2025 | 639.1 | 649.7 | 633.3 | 645.4 | 30,436 | 92,21,00,923.4 | 8,54,454 |
19-May-2025 | 645.4 | 649 | 641 | 642 | 14,206 | 27,92,20,761.65 | 2,25,982 |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
